Independent DSMB identifies no safety concerns, and recommends continuation of BriaCell’s pivotal Phase 3 study of Bria-IMT™ plus immune check...
- RDEB is a lifelong debilitating, blistering skin disease associated with large and painful wounds that often remain open for...
Comprehensive restructuring eliminates the potential issuance of up to 1.5 billion shares of common stock Plus Therapeutics files a request...
Initiative aims to expand and encourage philanthropy to help patients with retinal diseases afford their medicationsTARRYTOWN, N.Y., June 24, 2025...
C-FORWARD is the Second Phase 3 Trial in the Global HCV Development Program; the First Phase 3 Trial, C-BEYOND, is...
Flexible funding provides $2 billion in committed capital comprised of up to $1.25 billion of synthetic royalty and up to...
OSLO, Norway, June 24, 2025 (GLOBE NEWSWIRE) -- EXACT Therapeutics (Euronext Growth: EXTX), a clinical-stage precision medicine company, is pleased...
For media and investors only Researchers identified variants which may cause activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS)Results enable clinical...
SOUTH SAN FRANCISCO, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing next-generation...
KANSAS CITY, Mo.--(BUSINESS WIRE)--#AIinHealthcare--Trially®, a breakthrough AI clinical trial recruitment technology to unlock faster qualified patient enrollment, today announced the...
WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (Nasdaq: TLSI), a company working to improve outcomes for patients with solid tumors by...
SHARJAH, UAE, June 23, 2025 /PRNewswire/ -- Koning Health is proud to announce the installation of the Koning Vera at the...
BOSTON, June 23, 2025 /PRNewswire/ -- TOBY, Inc., a biotechnology company focusing on improving early cancer screening, today announced its...
Multi-center, multi-national study builds on existing U.S. PE Clearance and CE Mark to assess mechanical thrombectomy treatment and long-term functional...
GE HealthCare continues to advance precision care in cardiology through innovative molecular imaging solutions to help support early diagnosis, tailored...
Breakthrough Therapy Designation based on promising early clinical evidence observed with daraxonrasib in patients with pancreatic ductal adenocarcinoma (PDAC) RASolute...
June 23, 2025 Biodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 Study In Familial Adenomatous Polyposis (FAP)...
TORONTO, June 23, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0)...
Provides Update on SKNJCT-003 Phase 2 Clinical Study for the Treatment of Basal Cell Carcinoma (BCC) Using Novel Doxorubicin Containing...
GE HealthCare is helping advance clinical and operational excellence in theranostics and molecular imaging through a comprehensive portfolio of AI-powered...